Table 1

The distribution of NFSs in NHANES III participants with NAFLD

VariablesHigh NFS*Low or Med NFS†ProbabilityOverall NAFLD cohort
Demographic data
 N12923862515
 Age, years62.78±11.0947.96±15.330.000048.72±15.48
 Race
  White59 (45.7%)838 (35.1%)0.0142897 (35.7%)
  Black39 (30.2%)506 (21.2%)0.0154545 (21.7%)
  Hispanic26 (20.2%)951 (39.9%)0.0000977 (38.8%)
 Male42 (32.6%)1166 (48.9%)0.00031208 (48.0%)
Clinical data
 BMI37.304±9.39530.214±6.2740.000030.577±6.654
 Waist circumference, cm116.884±16.416101.322±14.8530.0000102.097±15.310
 Obesity100 (77.5%)1115 (46.7%)0.00001215 (48.3%)
 Glucose, mg/dL165.429±91.884112.727±51.7490.0000115.434±55.734
 Insulin27.552±21.13918.164± +/-19.8340.000018.649±20.007
 Homeostasis Model Assessment12.337±14.4405.670±11.0230.00006.015±11.318
 Total cholesterol, mg/dL214.674±49.724212.407±45.6460.8328212.523±45.856
 HDL, mg/dL47.685±20.34845.458±13.9730.594045.571±14.369
 LDL, mg/dL120.212±33.238130.079±37.8880.1113129.564±37.708
 Hypercholesterolaemia108 (83.7%)1968 (82.5%)0.71792076 (82.5%)
 Triglyceride, mg/dL222.233±186.609195.818±141.8210.1597197.173±144.529
 AST, IU/L29.512±31.73324.363±15.7370.604424.627±16.956
 ALT, IU/L18.318±14.75824.006±21.0720.000023.714±20.830
 Elevated liver enzymes27 (20.9%)404 (16.9%)0.2405431 (17.1%)
 Serum albumin, g/dL3.864±0.3564.144±0.3650.00004.129±0.370
 Platelet count, ×109203.589±55.424283.519±71.0180.0000279.419±72.472
 Hypertension84 (65.1%)864 (36.2%)0.0000948 (37.7%)
 Diabetes97 (75.2%)421 (17.6%)0.0000518 (20.6%)
 Metabolic syndrome76 (80.0%)1153 (55.5%)0.00001229 (56.6%)
 CHF18 (14.2%)90 (3.8%)0.0000108 (4.3%)
 Stroke9 (7.0%)62 (2.6%)0.003571 (2.8%)
 Smoking18 (14.0%)512 (21.5%)0.0416530 (21.1%)
 Non-Alcoholic Fatty Liver Score1.536±0.836−2.079±1.3990.0000−1.894±1.590
Mortality data
 Months of follow-up151.357±78.005210.950±56.8080.0000207.891±59.535
 Die87 (67.4%)667 (28.0%)0.0000754 (30.0%)
  • *High NFS defined as NFS >0.676.

  • †Low or medium NFS defined as NFS ≤0.676.

  • ALT, alanine  aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CHF, congestive heart failure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD Fibrosis Score; NHANES III, National Health and Nutrition Examination Survey.